Erratum: Legal approaches regarding health-care decisions involving minors: implications for next-generation sequencing

ABSTRACTLivestock-associated methicillin-resistantStaphylococcus aureus(LA-MRSA) was detected in 2003 and rapidly became the predominant MRSA clade in the Netherlands. Studies have shown that transmissions are difficult to identify, since this MRSA variant represents a genetically homogenous clade when current typing techniques are used. Here, next-generation sequencing was performed on 206 LA-MRSA isolates to assess the capability of LA-MRSA to be transmitted between humans. The usefulness of single nucleotide variants (SNVs), the composition of the SCCmecregion, and the presence of plasmids to identify transmission of LA-MRSA were assessed. In total, 30 presumed putative nosocomial transmission events and 2 LA-MRSA outbreaks were studied; in most cases, SNV analysis revealed that the isolates of the index patient and the contact(s) clustered closely together. In three presumed events, the isolates did not cluster together, indicating that transmission was unlikely. The composition of the SCCmecregion corroborated these findings. However, plasmid identification did not support our SNV analysis, since different plasmids were present in several cases where SNV and SCCmecanalysis suggested that transmission was likely. Next-generation sequencing shows that transmission of LA-MRSA does occur in Dutch health care settings. Transmission was identified based on SNV analysis combined with epidemiological data and in the context of epidemiologically related and unrelated isolates. Analysis of the SCCmecregion provided limited, albeit useful, information to corroborate conclusions on transmissions, but plasmid identification did not.IMPORTANCEIn 2003, a variant of methicillin-resistantStaphylococcus aureus(MRSA) isolated from pigs was also found in pig farmers in France and the Netherlands. Soon thereafter, this livestock-associated MRSA (LA-MRSA) was identified in many other countries. Transmission of LA-MRSA between humans, particularly in the health care setting, is regarded to occur sporadically. Moreover, studies that describe LA-MRSA transmission used molecular characterization of isolates with limited discriminatory power, making the validity of the conclusion that transmission occurred questionable. In our study, we sequenced the complete genomes of 206 LA-MRSA isolates, obtained from more than 30 presumed LA-MRSA transmission events. Analysis of the data showed that transmission of LA-MRSA between humans had indeed occurred in more than 90% of these events. We conclude that transmission of LA-MRSA between humans does occur in Dutch health care settings; therefore, a decision to discontinue the search and destroy policy for LA-MRSA should be taken with caution.

Download Full-text

Guía de Procedimientos Operacionales y Recomendaciones en la Implementación de Secuenciación de Nueva Generación para Diagnóstico Clínico

Revista Médica de Panamá - ISSN 2412-642X ◽

10.37980/im.journal.rmdp.2019778 ◽

2019 ◽

Vol 39 (1) ◽

Author(s):

Jorge David Mendez-Rios

Keyword(s):

Health Care ◽

Next Generation Sequencing ◽

Health Care Professionals ◽

Clinical Diagnostics ◽

Next Generation ◽

Efficient Tool ◽

Starting Point ◽

Control Procedures ◽

Recursos Humanos ◽

Generation Sequencing

[Standard Operational Procedures and Recommendations on Next Generation Sequencing for Clinical Diagnostics]ResumenLa tecnología diagnóstica conocida como NGS por sus siglas en inglés, o Secuenciación de nueva generación, es relativamente nueva, y se está implementando en algunos hospitales de Panamá. Esta tecnología a demostrado ser una herramienta muy eficiente para la detección de alteraciones genómicas o exómicas, tanto para la clínica como para la investigación. Dada la complejidad de esta prueba, requiere una infraestructura y un número significativo de recursos humanos para poder implementar esta prueba. El propósito de este documento es establecer un marco de referencia para los procedimientos administrativos en cuanto a la realización de las pruebas de secuenciación por metodología NGS. A demás, servirá de punto de inicio para el establecimiento de programas internos de control de calidad y evaluación de calidad que la metodología requiere en nuestro país. SummaryThe technology known as Next-Generation sequencing is relatively new, and it is being implemented in a few Panamenian hospitals. It has demonstrated to be a very efficient tool to identify genomic and exomic variants in a clinical setting as for research. Because of its complexity, it requires an important infrastructure and a significant number of trained health-care professionals to carry out this test. The purpose of this document is to establish the first work frame for the administrative aspects for NGS diagnosis. Moreover, it will serve as a starting point to establish quality control procedures that the technology requires.*

Download Full-text

Next-generation sequencing in health-care delivery: lessons from the functional analysis of rhodopsin

Genetics in Medicine ◽

10.1038/gim.2012.73 ◽

2012 ◽

Vol 14 (11) ◽

pp. 891-899 ◽

Cited By ~ 21

Author(s):

Wayne I.L. Davies ◽

Susan M. Downes ◽

Josephine K. Fu ◽

Morag E. Shanks ◽

Richard R. Copley ◽

...

Keyword(s):

Health Care ◽

Functional Analysis ◽

Next Generation Sequencing ◽

Health Care Delivery ◽

Care Delivery ◽

Next Generation ◽

Generation Sequencing

Download Full-text

Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital

Cancers ◽

10.3390/cancers13051121 ◽

2021 ◽

Vol 13 (5) ◽

pp. 1121

Author(s):

Chiaki Inagaki ◽

Daichi Maeda ◽

Kazue Hatake ◽

Yuki Sato ◽

Kae Hashimoto ◽

...

Keyword(s):

Health Care ◽

Next Generation Sequencing ◽

Health Care System ◽

Treatment Recommendation ◽

Universal Health Care ◽

Next Generation ◽

Universal Health Care System ◽

Universal Health ◽

Generation Sequencing ◽

Care System

Next-generation sequencing (NGS) assay is part of routine care in Japan owing to its reimbursement by Japan’s universal health-care system; however, reimbursement is limited to patients who finished standard treatment. We retrospectively investigated 221 patients who underwent Foundation One CDX (F1CDx) at our hospital. Every F1CDx result was assessed at the molecular tumor board (MTB) for treatment recommendation. Based on patients’ preferences, presumed germline findings were also assessed at the MTB and disclosed at the clinic. In total, 204 patients underwent F1CDx and 195 patients completed the analysis; however, 13.8% of them could not receive the report due to disease progression. Among 168 patients who received the results, 41.6% had at least one actionable alteration, and 3.6% received genomically matched treatment. Presumed germline findings were nominated in 24 patients, and 16.7% of them contacted a geneticist counselor. The NGS assay should be performed earlier in the clinical course to maximize the clinical benefit. Broader reimbursement for the NGS assay would enhance the delivery of precision oncology to patients. Access to clinical trials affects the number of patients who benefit from NGS. Additionally, the disclosure of presumed germline findings is feasible in clinical practice.

Download Full-text